Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Total Non-current Liabilities
All obligations due after more than one year.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities rises 19.8% from a year ago
Total non-current liabilities stood at $8.19M at the end of Q1 FY2026, up 19.8% from a year earlier and down 6.2% from the prior quarter. Over 3 fiscal years it compounded at -5.8% a year.
Context
- Total non-current liabilities amounted to 1.6% of total assets at the end of Q1 FY2026, down 0.6 pp from a year earlier.
- Total non-current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +19.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 8.73M USD
- Year-over-year change
- +1081.2%
- 3-year CAGR
- -5.8%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.73M | +1081.2% |
| FY2024 | 2024-12-31 | 739K | -99.6% |
| FY2023 | 2023-12-31 | 172.25M | +1550.7% |
| FY2022 | 2022-12-31 | 10.44M | — |
Total Non-current Liabilities vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's Mar 2026 total non-current liabilities of $8.19M is the 5th highest of the 10 companies compared; the peer median is $4.67M.
- Its year-over-year change of +19.8% is the 2nd highest of 8, against a peer median of -16.4%.
- Total non-current liabilities amounts to 1.6% of total assets for RAPP, versus a peer median of 1.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $217.7M | -3.1% | +21.1% | 28.6% | |
| Sep 2026 | $74.45M | +30.8% | -1.1% | 4.1% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $53.08M | — | -59.9% | 34.5% |
| Mar 2026 | $19.78M | -22.6% | -35.7% | 7.2% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $8.19M | +19.8% | -5.8% | 1.6% |
| Mar 2026 | $4.67M | -16.4% | -6.1% | 1.1% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $4.65M | +2.3% | +15.7% | 1.8% |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $3.88M | -21.7% | -56.2% | 1.0% |
| Mar 2026 | $176K | -37.1% | -56.6% | 0.5% | |
| Sep 2026 | $0 | — | — | 0.0% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding RAPP) | $4.67M | -16.4% | -20.9% | 1.8% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.